Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A perspective on the use of concentration-QT modeling in drug development.

× No keyword cloud information.

5 in total

1. Estimation of QT interval prolongation through model-averaging.

Authors: Peter L Bonate
Journal: J Pharmacokinet Pharmacodyn Date: 2017-04-18 Impact factor: 2.745

2. Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates.

Authors: Puneet Gaitonde; Yeamin Huh; Borje Darpo; Georg Ferber; Günter Heimann; James Li; Kaifeng Lu; Bernard Sebastien; Kuenhi Tsai; Steve Riley
Journal: J Pharmacokinet Pharmacodyn Date: 2019-10-30 Impact factor: 2.745

3. Moxifloxacin versus placebo modeling of the QT interval.

Authors: Philippe Grosjean; Saïk Urien
Journal: J Pharmacokinet Pharmacodyn Date: 2012-02-17 Impact factor: 2.745

4. Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.

Authors: Shuying Yang; Misba Beerahee
Journal: Eur J Clin Pharmacol Date: 2013-01-17 Impact factor: 2.953

5. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Authors: Rashmi Mehta; Michelle Green; Bela Patel; Jonathan Wagg
Journal: J Pharmacokinet Pharmacodyn Date: 2016-01-06 Impact factor: 2.745

5 in total